dengu
viru
denv
repres
major
mosquitoborn
pathogen
respons
signific
public
health
socioeconom
burden
larg
region
tropic
subtrop
four
distinct
serotyp
transmit
mainli
mosquito
aed
speci
continu
spread
new
geograph
area
around
world
health
organ
estim
preval
million
case
denv
infect
per
year
howev
recent
global
estim
studi
suggest
million
denv
infect
occur
annual
million
case
clear
denv
infect
caus
wide
rang
clinic
symptom
acut
febril
ill
dengu
fever
lifethreaten
haemorrhag
feverdengu
shock
date
clinic
approv
therapeut
option
treat
denvinfect
patient
still
lack
denv
envelop
singlestrand
positivesens
rna
viru
belong
flaviviru
genu
famili
genu
flaviviru
compris
mani
import
emerg
arbovirus
includ
japanes
enceph
viru
west
nile
viru
zika
viru
zikv
recent
zikv
infect
emerg
global
public
health
concern
due
associ
newborn
neurolog
sequela
syndrom
meningoenceph
myeliti
infect
flaviviru
genom
approxim
kb
length
encod
polyprotein
process
three
structur
capsid
c
premembran
prm
envelop
e
seven
nonstructur
protein
cellular
viral
flaviviru
infect
initi
attach
viru
cellular
receptor
plasma
membran
follow
receptormedi
endocytosi
transport
viral
particl
viral
membran
fusion
endosom
membran
trigger
upon
exposur
viru
lowph
environ
endosom
viral
genom
releas
follow
rna
replic
protein
translat
immatur
virion
contain
prm
protein
assembl
within
endoplasm
reticulum
er
matur
passag
acid
environ
transgolgi
network
tgn
wherein
e
protein
undergo
conform
chang
pr
peptid
cleav
furin
endoproteas
progeni
virion
releas
host
well
establish
neutral
acid
tgn
environ
prevent
furin
cleavag
result
immatur
particl
contain
uncleav
prm
immatur
particl
noninfecti
sinc
uncleav
prm
peptid
block
lowphinduc
conform
chang
viral
e
protein
essenti
bind
cell
surfac
well
membran
fusion
viru
thu
sever
studi
shown
lysosomotrop
agent
chloroquin
exert
modest
antivir
effect
phdepend
virus
includ
flavivirus
interf
endosom
fusion
furindepend
matur
vivo
recent
niclosamid
us
food
drug
administr
fda
approv
antiparasit
drug
use
identifi
effect
antivir
agent
number
phdepend
virus
human
rhinovirus
influenza
sever
acut
respiratori
chikungunya
studi
suggest
broad
antivir
activ
niclosamid
associ
neutral
endolysosom
ph
interfer
phdepend
membran
fusion
critic
step
viru
recent
studi
kao
et
determin
inhibitori
role
endosom
deacidif
denv
viral
genom
replic
uncoat
later
step
viral
life
cycl
therefor
possibl
effect
niclosamideinduc
neutral
endosom
compart
later
stage
denv
infecti
cycl
remain
elucid
studi
investig
confirm
neutral
lowph
intracellular
compart
niclosamid
affect
multipl
step
denv
infecti
cycl
data
indic
niclosamideinduc
endosom
neutral
prevent
viral
genom
releas
replic
well
matur
denv
particl
render
noninfecti
specif
found
niclosamideinduc
endosom
neutral
block
conform
chang
e
glycoprotein
virion
surfac
denv
zikv
result
releas
immatur
viru
particl
uncleav
pr
peptid
prevent
infect
new
host
cell
collect
find
support
potenti
applic
niclosamid
antivir
agent
flaviviru
infect
highlight
previous
uncharacter
mechan
action
drug
studi
antidengu
activ
niclosamid
evalu
use
four
denv
serotyp
h
postinfect
pi
viral
titr
supernat
number
infect
cell
measur
fluorescenceactiv
cell
sorter
fac
analysi
focusform
assay
respect
proport
cell
posit
denv
antigen
decreas
dosedepend
manner
cell
treat
niclosamid
compar
dmsotreat
control
determin
fac
analysi
fig
specif
percentag
denvposit
cell
significantli
reduc
infect
cell
treat
niclosamid
concentr
higher
four
serotyp
denv
fig
valu
niclosamid
approxim
respect
rule
possibl
viru
infect
cell
sensit
niclosamid
treatment
result
synergist
cytotox
compar
mockinfect
cell
percentag
live
dead
cell
mock
infect
cultur
increas
concentr
niclosamid
determin
fac
analysi
data
show
differ
cell
viabil
mock
denvinfect
cell
treat
increas
concentr
niclosamid
supplementari
fig
next
cytotox
concentr
valu
niclosamid
determin
measur
cell
viabil
use
mtt
assay
estim
valu
niclosamid
howev
minor
cytotox
effect
subleth
dose
observ
cell
supplementari
fig
similarli
niclosamid
inhibit
product
infecti
denv
particl
four
serotyp
dosedepend
manner
quantifi
focusform
assay
significantli
infecti
denv
particl
detect
infect
cell
treat
niclosamid
concentr
higher
fig
result
togeth
confirm
niclosamid
effect
inhibit
denv
infect
independ
viru
serotyp
within
noncytotox
rang
cell
demonstr
niclosamid
antivir
effect
denv
independ
serotyp
ngc
strain
employ
subsequ
experi
perform
timeofaddit
experi
investig
stage
denv
life
cycl
niclosamid
exert
antivir
activ
cell
infect
subsequ
treat
niclosamid
start
h
pi
medium
cell
lysat
harvest
h
pi
fig
analysi
infecti
progeni
releas
supernat
reveal
niclosamid
affect
earli
stage
viral
life
cycl
also
reduc
progeni
titr
ad
later
stage
specif
complet
inhibit
infecti
viru
product
niclosamid
ad
h
pi
reduct
observ
niclosamid
treatment
initi
late
h
pi
fig
similarli
niclosamid
treatment
maxim
effect
reduc
intracellular
viral
rna
ad
h
pi
inhibitori
effect
markedli
decreas
drug
ad
later
time
point
h
pi
suggest
niclosamid
interfer
viral
rna
replic
fig
likewis
mark
reduct
viral
genom
copi
releas
supernat
sampl
receiv
niclosamid
treatment
h
pi
reduct
effect
diminish
drug
ad
later
time
point
late
h
pi
reduct
fig
thu
data
togeth
indic
niclosamid
possibl
inhibit
viral
rna
replic
ad
earli
step
viral
life
cycl
also
affect
late
stage
virion
biogenesi
matur
sinc
strong
antivir
effect
consist
observ
infect
cell
niclosamid
treatment
start
late
h
pi
fig
addit
viral
e
protein
level
significantli
reduc
upon
niclosamid
treatment
earli
postinfect
time
point
wherea
antivir
effect
diminish
drug
ad
h
pi
fig
taken
togeth
data
suggest
niclosamid
potent
inhibit
earli
stage
denv
life
cycl
impact
viral
rna
accumul
protein
express
well
product
infecti
virus
addit
data
reveal
niclosamid
affect
earli
stage
also
late
stage
denv
life
cycl
independ
effect
intracellular
viral
rna
accumul
protein
synthesi
niclosamid
proton
carrier
block
endosom
test
whether
niclosamid
neutral
lowph
compart
cell
use
acridin
orang
ao
fluoresc
phsensit
dye
shown
fig
low
ph
endosom
red
present
mocktreat
cell
complet
absent
cell
treat
niclosamid
green
suggest
effect
block
endosom
acidif
cell
bafilomycin
ammonium
chlorid
use
control
confirm
correl
antivir
effect
neutral
endosom
ph
lysotrack
marker
acid
compart
analysi
perform
togeth
immunofluoresc
stain
detect
doublestrand
rna
dsrna
denvinfect
cell
treat
niclosamid
earli
pre
h
h
pi
late
stage
post
h
pi
h
pi
fig
result
show
viral
dsrna
express
intermedi
product
replic
significantli
inhibit
infect
cell
treat
niclosamid
earli
late
stage
compar
dmsotreat
control
indic
viral
rna
replic
sever
affect
fig
notabl
differ
level
endosom
acidif
cell
treat
niclosamid
earli
stage
subsequ
remov
cultur
wherea
endosom
ph
effect
neutral
cell
receiv
treatment
late
stage
treatment
remain
lysotrack
stain
indic
revers
effect
drug
inhibit
endosom
acidif
fig
corrobor
suppress
viral
genom
replic
specif
due
niclosamideinduc
ph
neutral
denv
replicon
report
cell
encod
renilla
luciferas
gene
treat
niclosamid
time
point
indic
fig
ribavirin
broadspectrum
antivir
compound
known
imped
rna
viru
replic
use
posit
control
cell
viabil
replicon
cell
presenc
niclosamid
ribavirin
treatment
determin
mtt
assay
supplementari
fig
shown
fig
treatment
denv
replicon
report
cell
niclosamid
earli
time
point
pre
h
h
result
signific
reduct
luciferas
activ
compar
ribavirin
wherea
inhibitori
effect
almost
restor
level
dmsotreat
cell
cell
treat
niclosamid
h
cultur
post
h
pi
h
pi
contrast
reduct
luciferas
activ
reach
maximum
ribavirin
ad
h
pi
remain
cultur
harvest
thu
repliconbas
assay
suggest
niclosamid
inhibit
step
involv
viral
rna
replic
independ
effect
entri
membran
fusion
genom
releas
next
evalu
impact
niclosamid
proteolyt
activ
denv
play
essenti
role
viral
polyprotein
process
requir
initi
viral
replic
proteolyt
activ
denv
proteas
use
fluorogen
substrat
evalu
presenc
variou
concentr
niclosamid
result
halfmaxim
inhibitori
concentr
niclosamid
determin
show
modest
inhibit
proteas
activ
fig
lastli
express
level
denv
nonstructur
protein
niclosamid
treatment
earli
pre
h
h
pi
late
stage
post
h
pi
h
pi
examin
western
blot
analysi
fig
consist
immunofluoresc
assay
result
express
protein
significantli
reduc
cell
treat
earli
late
stage
although
inhibit
pronounc
cell
treat
earli
stage
viru
replic
treat
h
pi
fig
overal
data
indic
antivir
activ
niclosamid
earli
stage
denv
life
cycl
correl
neutral
profil
lowph
compart
suggest
block
endosom
acidif
result
inhibit
viral
genom
replic
polyprotein
process
imped
viral
protein
express
viru
product
corrobor
effect
niclosamideinduc
neutral
lowph
compart
virion
biogenesi
particularli
matur
phdepend
process
analys
composit
prm
e
protein
viru
particl
produc
infect
cell
treat
niclosamid
briefli
cell
treat
niclosamid
h
pi
supernat
collect
h
pi
subsequ
tissu
cultur
medium
obtain
niclosamidetr
mocktreat
cell
pellet
ultracentrifug
sampl
adjust
equal
viral
genom
copi
number
separ
sdspage
viral
protein
detect
western
blot
use
monoclon
antibodi
e
prm
protein
data
show
viru
particl
obtain
niclosamidetr
untreat
dmso
sampl
compar
level
denv
e
protein
fig
contrast
clear
prm
protein
band
approxim
kda
detect
denv
releas
niclosamidetr
cell
pr
peptid
cleav
matur
result
releas
immatur
noninfecti
viru
particl
medium
contrast
prm
protein
band
bare
detect
virion
releas
dmsotreat
cell
indic
matur
fulli
infecti
fig
next
morpholog
denv
particl
releas
dmso
niclosamidetr
cell
examin
transmiss
electron
microscopi
tem
shown
fig
denv
particl
deriv
dmsotreat
cell
rel
smooth
spikeless
outer
surfac
characterist
matur
particl
fig
c
upper
panel
compar
obtain
niclosamidetr
cell
expect
spiki
appear
immatur
particl
fig
c
lower
panel
similar
result
observ
human
monocyt
cellspecif
icamgrab
nonintegrin
cell
suggest
antivir
effect
niclosamid
limit
cell
supplementari
fig
taken
togeth
result
indic
inhibit
endosom
acidif
niclosamid
interfer
phdepend
denv
matur
process
prevent
cleavag
pr
peptid
protein
surfac
viru
hypothes
niclosamideinduc
neutral
lowph
compart
also
impact
zikv
member
flaviviru
genu
virion
biogenesi
first
corrobor
niclosamid
reduc
number
zikvposit
cell
infecti
viral
product
dosedepend
manner
cell
evalu
fac
analysi
focusform
assay
respect
fig
b
next
composit
prm
e
protein
zikv
virion
releas
medium
niclosamidetr
cell
examin
confirm
whether
niclosamid
impact
matur
process
shown
fig
zikv
particl
releas
medium
dmsotreat
cell
complet
process
detect
prm
protein
band
promin
protein
band
approxim
kda
observ
indic
virion
matur
fulli
infecti
contrast
zikv
particl
releas
medium
niclosamidetr
cell
promin
prm
protein
band
almost
protein
detect
indic
cleavag
pr
peptid
matur
process
hamper
fig
consist
result
electron
microscopi
imag
also
demonstr
virion
dmsotreat
cell
smoother
surfac
fig
upper
panel
obtain
niclosamidetr
cell
spiki
outer
surfac
fig
lower
panel
indic
conform
surfac
protein
chang
pr
peptid
cleavag
block
taken
togeth
data
suggest
niclosamideinduc
neutral
lowph
compart
interfer
denv
zikv
matur
process
result
releas
prmcontain
immatur
noninfecti
viral
particl
extracellular
environ
niclosamid
wellestablish
drug
safe
use
antihelmint
therapi
tapeworm
infect
approxim
antiparasit
activ
attribut
abil
inhibit
mitochondri
oxid
phosphoryl
anaerob
atp
product
affect
ph
homeostasi
recent
niclosamid
also
identifi
effect
antivir
agent
number
phdepend
virus
inhibitori
effect
attribut
neutral
endolysosom
ph
interfer
phdepend
membran
fusion
critic
viru
studi
found
neutral
lowph
intracellular
compart
niclosamid
inhibit
earli
stage
denv
viral
life
cycl
viral
rna
replic
independ
entri
step
also
late
stage
specif
matur
viru
particl
infecti
virion
similar
previou
report
data
show
niclosamid
neutral
lowph
intracellular
compart
revers
manner
suggest
antivir
effect
correl
neutral
acid
environ
critic
denv
confirm
niclosamid
effect
inhibit
intracellular
viral
rna
synthesi
protein
express
product
infecti
denv
particl
drug
ad
earli
time
point
infect
immunofluoresc
assay
coupl
stain
intracellular
acid
compart
live
denvinfect
cell
show
niclosamideinduc
ph
neutral
first
h
infect
suffici
complet
block
viral
dsrna
replic
subsequ
step
viral
protein
express
product
infecti
viral
particl
inde
niclosamid
treatment
first
h
infect
reduc
denv
replic
cell
harbour
dengu
replicon
level
compar
ribavirin
suggest
drug
affect
viral
rna
replic
andor
translat
independ
effect
entri
membran
fusion
genom
releas
furthermor
provid
evid
niclosamid
impair
proteolyt
activ
denv
essenti
initi
viral
replic
may
explain
effect
denv
genom
replic
andor
translat
strengthen
find
li
et
howev
find
somewhat
contradictori
result
report
kao
et
use
repliconbas
assay
indic
niclosamid
effect
denv
genom
replic
specul
varianc
efficaci
niclosamid
viral
genom
replic
use
repliconbas
cell
could
due
differ
time
drugaddit
use
studi
studi
identifi
new
potenti
interest
mode
action
niclosamid
impact
late
stage
viru
life
cycl
cell
timeofaddit
data
demonstr
quantiti
infecti
viru
particl
releas
media
significantli
reduc
even
niclosamid
ad
cell
sever
hour
infect
wherea
intracellular
extracellular
viral
rna
level
affect
extent
product
infecti
viru
particl
data
led
us
hypothesi
niclosamideinduc
intracellular
ph
neutral
affect
matur
denv
particl
extens
describ
lowphinduc
conform
rearrang
prm
e
protein
critic
denv
matur
inde
data
show
denv
well
zikv
particl
obtain
niclosamidetr
cell
contain
high
level
uncleav
prm
protein
compar
untreat
virion
suggest
viru
particl
immatur
noninfecti
similarli
transmiss
electron
microscopi
imag
show
denv
zikv
particl
secret
niclosamidetr
cell
substanti
larger
untreat
control
virion
irregular
surfac
indic
viral
particl
immatur
contain
uncleav
prm
surfac
taken
togeth
believ
provid
first
evid
neutral
lowph
intracellular
compart
niclosamid
prevent
conform
chang
e
glycoprotein
virion
surfac
flaviviru
matur
process
result
releas
immatur
noninfecti
viru
particl
host
cell
summari
confirm
antivir
effect
niclosamid
flavivirus
mostli
associ
neutral
lowph
intracellular
organel
consequ
multipl
phdepend
step
flaviviru
life
cycl
includ
viral
host
membran
fusion
uncoat
viral
rna
replic
inhibit
viral
polyprotein
process
matur
process
progeni
virion
impair
highlight
complex
antivir
efficaci
niclosamid
fig
collect
data
present
studi
provid
evid
support
repurpos
niclosamid
potenti
therapeut
option
phdepend
rna
virus
particularli
flavivirus
mosquito
cell
cell
maintain
minimum
essenti
medium
mem
invitrogen
carlsbad
ca
usa
supplement
foetal
bovin
serum
fb
hyclon
salt
lake
citi
ut
usa
respect
human
cell
purchas
japan
cell
research
bank
nation
institut
biomed
innov
health
nutrit
japan
maintain
highglucos
dulbecco
modifi
eagl
medium
dmem
hyclon
supplement
fb
cell
harbour
luciferaseexpress
denv
replicon
maintain
dmem
contain
fb
puromycin
invivogen
pak
shek
kok
hong
kong
obtain
korea
nation
institut
health
osong
republ
korea
new
guinea
c
strain
purchas
nation
collect
pathogen
virus
cultur
collect
public
health
england
salisburi
great
britain
purchas
korea
bank
pathogen
virus
kbpv
seoul
republ
korea
denv
propag
cell
tissu
cultur
fluid
tcf
supernat
harvest
day
postinfect
tcf
clarifi
centrifug
aliquot
store
use
viral
titr
quantifi
focusform
assay
cell
describ
zika
viru
strain
purchas
atcc
amplifi
viral
titr
measur
plaqu
assay
cell
determin
antivir
activ
niclosamid
cell
infect
zikv
multipl
infect
moi
treat
either
niclosamid
sigmaaldrich
st
loui
mo
usa
solvent
control
dimethyl
sulfoxid
dmso
sigmaaldrich
indic
concentr
doserespons
curv
obtain
serial
dilut
niclosamid
rang
h
pi
live
cell
cell
cultur
supernat
collect
process
flow
activ
cell
sorter
fac
analysi
viru
titrat
respect
cell
centrifug
g
min
resuspend
pb
cell
stain
ebiosci
fixabl
viabil
dye
efluor
invitrogen
ice
min
wash
twice
pb
subsequ
cell
incub
cytofixcytoperm
solut
bd
bioscienc
franklin
lake
nj
usa
ice
min
dark
cell
wash
permwash
buffer
bd
bioscienc
stain
antidenv
e
monoclon
antibodi
conjug
alexafluor
h
ice
subsequ
cell
express
denv
e
analys
facsaria
iii
flow
cytomet
bd
bioscienc
use
softwar
flowjo
llc
ashland
usa
sampl
least
event
collect
determin
mechan
action
niclosamid
cell
inocul
ngc
strain
moi
h
unbound
viru
remov
wash
icecold
phosphat
buffer
salin
pb
fresh
medium
ad
plate
shift
allow
synchron
entri
infect
soon
temperatur
shift
niclosamid
ad
h
maintain
throughout
infect
h
pi
cell
cultur
supernat
collect
viru
titrat
extracellular
viral
rna
quantif
focusform
assay
quantit
reversetranscript
polymeras
chain
reaction
rtqpcr
wherea
cell
lysat
harvest
subject
intracellular
viral
rna
viral
protein
analys
rtqpcr
western
blot
assay
respect
intracellular
viral
rna
quantif
total
cellular
rna
purifi
cell
lysat
use
rneasi
mini
kit
qiagen
valencia
ca
usa
accord
manufactur
instruct
viral
rna
tcf
sampl
extract
use
viral
rna
mini
kit
qiagen
accord
manufactur
instruct
rtqpcr
perform
use
superscript
iii
onestep
rtpcr
system
platinum
taq
polymeras
invitrogen
primersprob
set
target
e
gene
quantstudio
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
describ
rel
viral
rna
express
level
calcul
method
use
endogen
control
absolut
viral
rna
genom
copi
number
calcul
base
vitrotranscrib
denv
rna
standard
curv
report
absolut
number
viral
rna
genom
copi
per
ml
two
biolog
replic
technic
duplic
use
quantif
h
pi
virusinfect
cell
wash
pb
lyse
use
mper
buffer
thermo
fisher
scientif
waltham
usa
contain
proteas
inhibitor
cocktail
pierc
rockford
il
usa
cell
lysat
clarifi
centrifug
total
protein
content
determin
bradford
assay
biorad
hercul
ca
usa
equal
amount
protein
subject
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
electrotransf
pvdf
membran
viral
protein
detect
use
primari
antibodi
specif
denv
denv
e
denv
prm
zikv
e
zikv
prm
follow
horseradish
peroxidas
hrp
conjug
goat
antimous
antirabbit
secondari
antibodi
load
control
cellular
detect
primari
antibodi
hrpconjug
goat
antimous
secondari
antibodi
addit
chemiluminesc
hrp
substrat
supersign
west
pico
chemiluminesc
substrat
pierc
imag
obtain
use
luminesc
imag
analyz
fujifilm
tokyo
japan
cell
encod
luciferaseexpress
replicon
use
determin
denv
rna
replic
effici
briefli
replicon
cell
seed
plate
incub
differ
concentr
niclosamid
indic
time
point
h
incub
antivir
activ
measur
use
renilla
luciferas
assay
promega
madison
wi
usa
micropl
luminomet
tecan
switzerland
proteas
express
plasmid
use
studi
kindli
provid
dr
rolf
hilgenfeld
univers
germani
vitro
proteas
activ
assay
perform
describ
fluorogen
peptid
substrat
bocglyargargamc
purchas
bachem
ag
bubendorf
switzerland
measur
ph
chang
cytoplasm
membraneenclos
vesicl
cell
stain
acridin
orang
ao
thermo
fisher
scientif
describ
briefli
cell
cell
per
well
cultur
mm
glassbottom
dish
greiner
bioon
frickenhausen
germani
follow
day
cell
treat
h
niclosamid
nm
bafilomycin
vatpas
inhibitor
mm
ammonium
chlorid
intralysosom
phneutral
agent
acridin
orang
ad
cultur
medium
final
concentr
cell
imag
confoc
microscop
zeiss
meta
carl
zeiss
oberkochen
germani
excit
wavelength
nm
imag
collect
two
emiss
window
nm
nm
label
track
acid
organel
niclosamidetr
denvinfect
cell
deep
redfluoresc
dye
lysotrack
ltr
thermo
fisher
scientif
use
briefli
cell
grown
chamber
slide
incub
overnight
cell
infect
ngc
strain
moi
treat
niclosamid
h
prior
infect
left
cultur
h
pi
pre
h
treat
h
pi
treatment
maintain
throughout
cours
infect
h
incub
cell
wash
load
lysotrack
invitrogen
min
subsequ
cell
wash
pb
fix
paraformaldehyd
pb
min
room
temperatur
fix
cell
incub
antibodi
denv
e
protein
dsrna
antibodi
h
room
temperatur
cell
incub
goat
antimous
igg
antibodi
h
room
temperatur
nuclei
counterstain
incub
min
dapi
coverslip
mount
prolongtm
gold
antifad
reagent
invitrogen
imag
analysi
perform
use
confoc
microscop
zeiss
meta
cell
infect
ngc
strain
zikv
strain
moi
h
h
pi
niclosamid
dmso
ad
infect
cultur
incub
h
total
h
infect
viru
particl
pellet
ultracentrifug
beckman
type
rotor
g
h
virion
pellet
resuspend
nte
buffer
five
microlit
resuspend
zikv
mount
plasmaclean
mesh
carbonco
copper
grid
electron
microscopi
scienc
hatfield
pa
grid
wash
distil
water
neg
stain
aqueou
uranyl
acet
electron
microscopi
scienc
hatfield
pa
solut
blot
filter
paper
sampl
grid
rins
briefli
distil
water
three
time
dri
air
grid
examin
zeiss
transmiss
electron
microscop
carl
zeiss
acceler
voltag
kv
fei
tecnai
transmiss
electron
microscop
fei
compani
hillsboro
acceler
voltag
kv
statist
analys
perform
use
graphpad
prism
version
graphpad
softwar
la
jolla
ca
usa
effect
concentr
calcul
nonlinear
regress
analysi
data
set
analyz
use
oneway
anova
dunnett
test
multipl
comparison
signific
p
